Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children’s D...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2460578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542556520448000 |
|---|---|
| author | Filip Rob Blanka Pinkova Kristyna Sokolova Jana Kopuleta Zuzana Jiraskova Zakostelska Jana Cadova |
| author_facet | Filip Rob Blanka Pinkova Kristyna Sokolova Jana Kopuleta Zuzana Jiraskova Zakostelska Jana Cadova |
| author_sort | Filip Rob |
| collection | DOAJ |
| description | In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children’s Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2–42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8–13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6. |
| format | Article |
| id | doaj-art-ffde63a49e9b468ea6c6a294781deb28 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-ffde63a49e9b468ea6c6a294781deb282025-02-04T00:47:11ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2460578Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric studyFilip Rob0Blanka Pinkova1Kristyna Sokolova2Jana Kopuleta3Zuzana Jiraskova Zakostelska4Jana Cadova5Department of Dermatovenerology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech RepublicDepartment of Pediatric Dermatology, Faculty Hospital and Masaryk University Brno, Czech RepublicDepartment of Dermatovenerology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech RepublicDepartment of Pediatric Dermatology, Faculty Hospital and Masaryk University Brno, Czech RepublicLaboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech RepublicDepartment of Pediatric Dermatology, University Hospital Motol, Prague, Czech RepublicIn this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children’s Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2–42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8–13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.https://www.tandfonline.com/doi/10.1080/09546634.2025.2460578Atopic dermatitisdupilumabbiologicschildrenefficacysafety |
| spellingShingle | Filip Rob Blanka Pinkova Kristyna Sokolova Jana Kopuleta Zuzana Jiraskova Zakostelska Jana Cadova Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study Journal of Dermatological Treatment Atopic dermatitis dupilumab biologics children efficacy safety |
| title | Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study |
| title_full | Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study |
| title_fullStr | Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study |
| title_full_unstemmed | Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study |
| title_short | Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study |
| title_sort | real world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age a retrospective multicentric study |
| topic | Atopic dermatitis dupilumab biologics children efficacy safety |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2460578 |
| work_keys_str_mv | AT filiprob realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy AT blankapinkova realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy AT kristynasokolova realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy AT janakopuleta realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy AT zuzanajiraskovazakostelska realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy AT janacadova realworldefficacyandsafetyofdupilumabinchildrenwithatopicdermatitisunder6yearsofagearetrospectivemulticentricstudy |